CAPRELSA®( vandetanib )

Drug CAPRELSA® vandetanib Caprelsa Overview This is a summary of the European public assessment report (EPAR) for Caprelsa. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Caprelsa. How is Caprelsa used? […]

MEKINIST® (trametinib)

Drug MEKINIST® trametinib Mekinist Overview Mekinist is a cancer medicine used to treat adults whose cancer cells have a specific genetic mutation (change) in their genes called ‘BRAF V600’. It is used for the treatment of: melanoma (a skin cancer) that has spread or cannot be removed surgically. Mekinist is used on its own or […]

PEMETREXED ACCORD® (pemetrexed)

Drug PEMETREXED ACCORD® pemetrexed Pemetrexed Accord Overview This is a summary of the European public assessment report (EPAR) for Pemetrexed Accord. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Pemetrexed Accord. For practical […]

PAZENIR® (paclitaxel)

Drug PAZENIR® paclitaxel Pazenir Overview Pazenir is used to treat the following cancers in adults: metastatic breast cancer, when the first treatment has stopped working and standard treatment including an ‘anthracycline’ (another type of cancer medicine) is not suitable. ‘Metastatic’ means that the cancer has spread to other parts of the body; non-small cell lung […]

TAGRISSO® (osimertinib)

Drug TAGRISSO® osimertinib TAGRISSO Overview Tagrisso is medicine for treating a lung cancer called non-small cell lung cancer (NSCLC) when the cancer is advanced or has spread. It is used in patients who have mutations (changes) in a gene for a protein called EGFR. If a patient has mutations known as an ‘activating mutations’, Tagrisso […]

PORTRAZZA® (necitumumab)

Drug PORTRAZZA® necitumumab Portrazza Overview This is a summary of the European public assessment report (EPAR) for Portrazza. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Portrazza. For practical information about using Portrazza, […]

LORVIQUA® (lorlatinib)

Drug LORVIQUA® lorlatinib Lorviqua Overview Lorviqua is a cancer medicine used to treat adults with non-small cell lung cancer (NSCLC), when the disease is advanced and ‘ALK-positive’, which means that the cancer cells have certain changes affecting the gene responsible for a protein called ALK (anaplastic lymphoma kinase). Lorviqua is used on its own when […]

IRESSA® (gefitinib)

Drug IRESSA® gefitinib IRESSA Overview This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine. If you need more information about your medical condition or your treatment, read the package leaflet (also part of […]

TARCEVA® (erlotinib)

Drug TARCEVA® erlotinib Tarceva Overview Tarceva is a cancer medicine used in non‑small-cell lung cancer (NSCLC) that is advanced (the cancer has started to spread) or metastatic (it has already spread to other parts of the body). It is used for: previously untreated patients whose cancer cells have certain changes (‘activating mutations’) in the gene […]

TAFINLAR® (dabrafenib)

Drug TAFLINAR® dabrafenib Tafinlar Overview Tafinlar is a cancer medicine used to treat adults whose cancer cells have a specific genetic mutation (change) called ‘BRAF V600’. It is used for the treatment of: melanoma (a skin cancer) that has spread or cannot be removed surgically. Tafinlar is used on its own or in combination with […]